A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK

Annals of Oncology

Volumn 13, Issue 10, 2002, Pages 1590-1597

  Smith, D H ^a   Adams, J R ^a   Johnston, S R D ^a   Gordon, A ^a   Drummond, M F ^a   Bennett, C L ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Cost; Economic analysis; Ovarian cancer; PLD; Topotecan

Indexed keywords

DOXORUBICIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; PLATINUM; TOPOTECAN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; FEMALE; FEVER; HAND FOOT SYNDROME; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SENSITIVITY ANALYSIS; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; UNITED KINGDOM; UNITED STATES;

EID: 0036809016     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf275     Document Type: Article

References (31)

1. Bennett CL, Golub R, Waters TM et al. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997; 15: 227-236.
2. Drummond MF, Richardson WS, O'Brien BJ et al. Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997; 277: 1552-1557.
3. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15: 632-639.
4. McGuire W, Neugut AI, Arikian S et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640-645.
5. Stinson TJ, Calhoun E, Yang T et al. Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest 1999; 17: 559-565.
6. Mighion K, Gesme DH, Rifkin RM, Bennett CL. Growth of oncology physician practice management companies. Cancer Invest 1999; 17: 362-370.
7. Bennett CL, Stinson TJ, Lane D et al. A cost-analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol 1999; 34: 92-96.
8. Bennett CL, Stinson TJ, Tallman MS et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol 1999; 10: 177-182.
9. Bennett CL, Hynes D, Godwin J et al. Economic analysis of granulocyte colony stimulating factor for older patients with acute myelogenous leukemia: estimates from a Southwest Oncology Group clinical trial. Cancer Invest 2001; 19: 611-618.
10. Ozols RF, Schwartz PE, Eifel PJ. Treatment of advanced-stage ovarian cancer. In DeVita VT, Hellman S, Rosenberg SA et al. (eds). Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997; 1514-1539.
11. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-1557.
12. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2000; 18: 1062-1067.
13. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 20: 3312-3322.
14. Briggs AH, O'Brien BJ. The death of cost-mimimization analysis? Health Econ 2001; 10: 179-184.
15. British Medical Association. British National Formulary 37. London: BMJ Books; 1999.
16. NHS Executive. The New NHS 1999 Reference Costs (CD-ROM). Catalogue number 10756. Leeds: NHS Executive; 1999.
17. Edbrooke D, Hibbert C, Kingsley J et al. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care. Crit Care Med 1999; 27: 1760-1767.
18. Medical Economics, Inc. 2000 Red Book. Montvale, NJ: Medical Economics Company, Inc.; 2000.
19. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34: 1857-1864.
20. O'Brien BJ, Willan A, Blackhouse G et al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000; 139: 423-429.
21. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998; 3: 233-245.
22. Briggs A, Wonderling D, Mooney C. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327-340.
23. Briggs A, Gray A. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999; 3: 1-134.
24. Institute of Public Finance. CIPFA/HFM Health Database. 1999.
25. Adams JR, Elting LS, Lyons T et al. Evaluation of EPO use and direct-to-consumer marketing effects: results from a survey of American and international hemotologists and oncologists. Proc Am Soc Clin Oncol 2001; 20: 994A.
26. Bennett CL, Golub RM, Stinson TJ et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 460-465.
27. Bennett CL, Armitage JL, LeSage S et al. Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells 1994; 12: 424-429.
28. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J 1996; 313: 275.
29. Bennett CL, Stinson TJ. Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the GOG 111 trial. Cancer Invest 1999; 108: 263-270.
30. O'Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Manag Care 1997; 3 (Suppl): S33-S39.
31. Calhoun EA, Welshman EE, Chang C et al. Cost of chemotherapy induced neutropenia, thrombocytopenia, and neurotoxicity. Proc Am Soc Clin Oncol 2001; 20: 242A.